Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Black death

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: Black death. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2016-003339-39 Sponsor Protocol Number: EHDA-01 Start Date*: 2017-05-03
    Sponsor Name:JOSÉ MARÍA PALAZÓN AZORÍN
    Full Title: A randomized, controlled and double-blind trial of intravenous azithromycin versus intravenous erythromycin as a single dose prior to endoscopy in upper gastrointestinal bleeding
    Medical condition: Upper gastrointestinal haemorrhage
    Disease: Version SOC Term Classification Code Term Level
    19.1 10017947 - Gastrointestinal disorders 10046274 Upper gastrointestinal haemorrhage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005492-12 Sponsor Protocol Number: BDTX-189-01 Start Date*: 2021-05-27
    Sponsor Name:Black Diamond Therapeutics, Inc.
    Full Title: MasterKey-01: A Phase 1/2, Open-label, Two-part, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutation...
    Medical condition: NSCLC, breast cancer, biliary tract cancer, or cervical cancer, any other solid tumors with specific gene mutations
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) NL (Prematurely Ended) ES (Completed) IT (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-005532-18 Sponsor Protocol Number: PLX-CLI-03 Start Date*: 2017-01-02
    Sponsor Name:Pluristem Ltd.
    Full Title: A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Phase III Study to Evaluate the Efficacy, Tolerability and Safety of Intramuscular Injections of PLX-PAD for the Treatmen...
    Medical condition: Critical Limb Ischemia (CLI)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10058069 Critical limb ischemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) AT (Completed) HU (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003628-18 Sponsor Protocol Number: 000000 Start Date*: 2020-09-29
    Sponsor Name:University of Oxford, Clinical Trials and Research Governance
    Full Title: Adalimumab in COVID-19 to present respiratory failure in community care (AVID-CC): A randomised controlled trial
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    20.0 10022891 - Investigations 10070255 Coronavirus test positive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2013-002696-18 Sponsor Protocol Number: SUN101-303 Start Date*: 2013-12-18
    Sponsor Name:Sunovion Respiratory Development Inc.
    Full Title: A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter, Long-Term Safety Trial of Treatment with Nebulized SUN-101 in Patients with COPD: GOLDEN-5 (Glycopyrrolate for Obstructive ...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-000432-17 Sponsor Protocol Number: 8.0 Start Date*: 2017-03-29
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in ...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035226 Plasma cell myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005504-18 Sponsor Protocol Number: APHP201185 Start Date*: 2021-05-21
    Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP)
    Full Title: Lenvatinib in neo-adjuvant and adjuvant therapy for poor-prognosis BCLC A HepatoCellular Carcinoma treated by ablative procedure in a curative intent: multicentre phase 2 therapeutic trial
    Medical condition: NA
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001737-27 Sponsor Protocol Number: 54767414AMY3001 Start Date*: 2018-04-16
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnos...
    Medical condition: AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis )
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10002022 Amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) GR (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005798-36 Sponsor Protocol Number: HOVON100ALL/EORTC06083 Start Date*: 2009-08-31
    Sponsor Name:HOVON Foundation
    Full Title: Clofarabine added to prephase and consolidation therapy in acute lymphoblastic leukemia in adults.
    Medical condition: Primary previously untreated B or T-lineage ALL (excluding ALL with mature B-cell phenotype, but including Philadelphia positive or BCR-ABL positive ALL) or previously untreated T-LBL
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    17.0 100000004864 10043028 T-lymphoblastic lymphoma (Kiel Classification) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019742-12 Sponsor Protocol Number: GIMEMALAL1610 Start Date*: 2012-06-06
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
    Full Title: A Phase II study with a sequential clofarabine-cyclophosphamide combination schedule as salvage therapy for refractory and relapsed acute lymphoblastic leukemia (ALL) in adult patients
    Medical condition: Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004260-36 Sponsor Protocol Number: MS100070_0160 Start Date*: 2018-03-12
    Sponsor Name:Associació Per a la Recerca Oncològica (APRO)
    Full Title: Phase II multicentre, randomized, open-label study to evaluate the safety and efficacy of avelumab with gemcitabine/carboplatin versus gemcitabine/carboplatin alone in patients with unresectable or...
    Medical condition: Unresectable or metastatic urothelial carcinoma in patients without prior systemic therapy and who are ineligible to receive cisplatin-based therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-002843-26 Sponsor Protocol Number: HO132AML/SAKK30/13 Start Date*: 2014-03-27
    Sponsor Name:HOVON Foundation
    Full Title: Randomized study with a run-in dose-selection phase to assess the added value of lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients ...
    Medical condition: previously untreated acute myeloid leukemia (AML) or high risk myelodysplasie (MDS)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10000886 Acute myeloid leukemia LLT
    18.1 100000004864 10028532 Myelodysplasia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Prematurely Ended) LT (Prohibited by CA) SE (Ongoing) FI (Prematurely Ended) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017347-33 Sponsor Protocol Number: Clofarabine Start Date*: Information not available in EudraCT
    Sponsor Name:University of Leipzig
    Full Title: A multicenter Phase I/II trial investigating the safety and efficacy (CR rate and OS) of low dose AraC with Clofarabine in patients ≥60 years with AML not eligible for conventional Chemotherapy
    Medical condition: Acute myeloid leukaemia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10000880 Acute myeloid leukaemia PT
    12.1 10000880 Acute myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004842-92 Sponsor Protocol Number: SECOMBIT Start Date*: 2016-06-30
    Sponsor Name:FONDAZIONE MELANOMA ONLUS
    Full Title: A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy (ipilimumab/nivolumab) and combo target therapy (LGX818/MEK162) in patients wit...
    Medical condition: Metastatic melanoma and BRAF mutation
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Ongoing) DE (Completed) GR (Completed) AT (Prematurely Ended) GB (GB - no longer in EU/EEA) SE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011613-24 Sponsor Protocol Number: HOVON102AML/SAKK30/09 Start Date*: 2010-01-25
    Sponsor Name:HOVON Foundation
    Full Title: Randomized study with a run-in feasibility phase to assess the added value of Clofarabine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously ...
    Medical condition: - a cytopathologically confirmed diagnosis of AML according WHO classification (excluding acute promyelocytic leukaemia) or - a diagnosis of refractory anemia with excess of blasts (RAEB) and ...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054592 Refractory anemia with an excess of blasts LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038270 Refractory anaemia with an excess of blasts PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066353 Treatment related acute myeloid leukemia LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002986-11 Sponsor Protocol Number: CAEB071A2203E1 Start Date*: 2007-09-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24 month extension to a 12-month open label, randomized, multicenter study evaluating efficacy, safety and tolerability of oral AEB071 plus tacrolimus (converted to myfortic® after 3 months), vs....
    Medical condition: The study is a continuation of a CNI-sparing study in which 2/3rds of patients were converted to a non CNI regimen after 3 months (core study). The others remained on a CNI Control arm. The extensi...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Prematurely Ended) DE (Prematurely Ended) IT (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002638-18 Sponsor Protocol Number: 20190288 Start Date*: 2021-10-14
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC Whose Tumors Harbor a KRASG12C Mutation in Need of First-line Treatment
    Medical condition: KRAS p.G12C mutant untreated stage IV Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Prematurely Ended) DE (Temporarily Halted) BE (Trial now transitioned) NL (Ongoing) SE (Trial now transitioned) DK (Prematurely Ended) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001876-75 Sponsor Protocol Number: HOVON103AMLSelinexor Start Date*: 2016-10-28
    Sponsor Name:HOVON Foundation
    Full Title: A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral selinexor (KPT-330) to standard induction chemotherapy in AML and high r...
    Medical condition: patients ≥ 66 years with: - a diagnosis of AML and related precursor neoplasms according to WHO 2008 classification (excluding acute promyelocytic leukemia) including secondary AML (after an antec...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10037803 RAEB LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002195-12 Sponsor Protocol Number: BNT111-01 Start Date*: 2021-04-27
    Sponsor Name:BioNTech SE
    Full Title: An open-label, randomized Phase II trial with BNT111 and cemiplimab in combination or as single agents in patients with anti-PD1-/ PD-L1-refractory/relapsed, unresectable Stage III or IV melanoma
    Medical condition: Anti-PD1-/ PD-L1-refractory/relapsed, unresectable Stage III or IV melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072449 Desmoplastic melanoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024220 Lentigo maligna recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024218 Lentigo maligna PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024223 Lentigo maligna stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024224 Lentigo maligna stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066600 Melanoma recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10079054 Naevoid melanoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029488 Nodular melanoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042551 Superficial spreading melanoma stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042552 Superficial spreading melanoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042553 Superficial spreading melanoma stage unspecified PT
    20.0 100000004858 10027156 Skin melanomas (excl ocular) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000452-34 Sponsor Protocol Number: 3004 Start Date*: 2013-11-19
    Sponsor Name:Steno Diabetes Center
    Full Title: Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuria
    Medical condition: Patients with type 2 diabetes mellitus and normoalbuminuria
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) IT (Completed) GB (Completed) NL (Completed) ES (Completed) CZ (Completed) GR (Completed) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 07:13:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA